Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01927757 · ClinicalTrials.gov registry record · Phase 4
Evaluating Etanercept Use in Patients With Moderate to Severe Rheumatoid Arthritis Who Have Lost Response to Adalimumab
A Phase 4 study, sponsored by Amgen.
- Terminated
- Registry status
- Phase 4
- Development phase
- 90
- Enrollment target
NCT01927757 is a Phase 4 study that was terminated before completion, run by Amgen. The registered enrollment target is 90 participants.
The verdict
NCT01927757, a Phase 4 study, was terminated before completion, sponsored by Amgen.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 90 participants
- Enrollment target
Study Summary
To evaluate the efficacy of etanercept in adults with moderate-to-severe rheumatoid arthritis (RA) who did not respond to or lost a satisfactory response to adalimumab when used as their first biologic agent.
Interventions
- BIOLOGICAL Etanercept
- DRUG Methotrexate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2013-05-06 |
| Est. Completion | 2015-06-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01927757
The ClinicalTrials.gov registry entry for NCT01927757 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Etanercept is the first listed.
NCT01927757 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01927757 about?
NCT01927757 is a clinical study titled "Evaluating Etanercept Use in Patients With Moderate to Severe Rheumatoid Arthritis Who Have Lost Response to Adalimumab". To evaluate the efficacy of etanercept in adults with moderate-to-severe rheumatoid arthritis (RA) who did not respond to or lost a satisfactory response to adalimumab when used as their first biologic agent.
What is the current status of trial NCT01927757?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 90 participants. The study started on 2013-05-06. Estimated completion is 2015-06-11.
What interventions are being tested in trial NCT01927757?
The interventions under investigation include: Etanercept (BIOLOGICAL), Methotrexate (DRUG).
Who is sponsoring clinical trial NCT01927757?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.